AbCellera Biologics Inc.

AbCellera Biologics Inc.

10.12
EUR
0.00
(0.00%)
-0.43EPS
4.23BMarket Cap
Feb 23Next Earn
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.04
0.05
1.46
1.36
1.7
0.13
0.1
0.25
0.22
Basic EPS, GAAP
- -
-0.01
0.53
0.56
0.56
-0.51
-0.55
-0.49
-0.48
Free Cash Flow per Basic Share
-0.01
-0.01
0.05
0.67
0.72
-0.42
-0.64
-0.58
-0.11
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.02
0.01
3.08
3.62
4.3
3.96
3.57
3.22
3.26
Tangible Book Value per Share
0.02
0.01
2.54
2.93
3.67
3.38
3.27
2.93
2.99
Basic Weighted Avg Shares
215
215
159
276
285
289
294
299
307
Sales/Revenue/Turnover
9
12
233
375
485
38
29
75
68
Operating Margin (%)
9.52
-20.18
70.49
59.14
46.78
-586.59
-1,044.45
-270.49
-275.65
Depreciation Expense
1
2
5
17
33
31
97
29
34
Net Income, GAAP
- -
-2
119
153
159
-146
-163
-146
-148
Effective Tax Rate (%)
- -
- -
24.66
29.97
33.7
- -
- -
- -
- -
Profit Margin (%)
3.5
-19.04
51
40.9
32.66
-385
-564.83
-194.88
-218.54
Working Capital
9
5
710
809
907
753
675
664
806
LT Debt
1
4
4
36
77
71
61
137
128
Total Equity
12
10
831
1,026
1,233
1,152
1,056
967
1,063
Return on Invested Capital (%)
- -
- -
26.47
14.51
11.88
- -
- -
- -
- -
Return on Capital (%)
- -
- -
29.07
16.53
13.54
- -
- -
- -
- -
Return on Common Equity (%)
- -
-65.43
20.43
16.53
14.03
-12.27
-14.75
-14.47
-14.64

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
6
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
134
130
128
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
304
306
326
Market Capitalization
1,055
2,415
4,793

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
665
679
876
Cash, Cash Equivalents & STI
505
540
764
Accounts Receivable, Net
37
19
18
Inventories
8
8
8
Total Current Liabilities
47
53
70
Payables & Accruals
25
18
22
ST Debt
6
6
6
Deferred Revenue
17
29
43

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.08%
-8.44%
Free Cash Flow
- -
423.91%
-6.89%
Net Income, GAAP
- -
-31.77%
-10.1%
Sales/Revenue/Turnover
- -
26.9%
160.56%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10
7
7
5
29
2025
4
17
9
45
75
2026
8
4
11
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.14
-0.13
-0.17
-0.12
-0.55
2025
-0.15
-0.12
-0.19
-0.03
-0.49
2026
-0.14
-0.18
-0.13
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Carl Lars G. Hansen
Full Time Employees
562
Sector
Health technology
Industry
Biotechnology
Address
150 W 4th Ave Vancouver BC Canada V5Y 1G6
IPO Date
Dec 11, 2020
Business
AbCellera Biologics Inc. (ABCL) is a biotechnology company that discovers and develops antibody-based therapeutics using proprietary AI-powered platforms for target discovery, antibody discovery, and optimization. The company offers integrated services including de novo antibody discovery from immune cells; computational protein design and engineering; and GPCR and ion channel screening technologies, with key partnerships supporting programs in oncology, metabolic and endocrine conditions, and autoimmune diseases. AbCellera operates primarily in North America and Europe, serving pharmaceutical and biotechnology partners; it was founded in 2012 and is headquartered in Vancouver, Canada. Core products and services encompass the AbCellera Engine platform, which combines microfluidics, deep learning AI, and single-cell analysis for rapid antibody isolation; proprietary FC Sort and FC Nano technologies for high-throughput functional screening; and end-to-end development support from discovery to preclinical candidates, including bispecific antibodies and antibody-drug conjugates under brands like those partnered with Eli Lilly and Novartis. The company targets large-molecule therapeutics across immunology, neurodegeneration, and infectious diseases, with a pipeline featuring wholly-owned assets such as ABCL635 for metabolic disorders and partnered programs advancing in Phase 1 trials. In the last 1-2 years, AbCellera expanded its strategic alliances, including a major multi-target collaboration with AbbVie in 2024 for immunology and neuroscience antibodies; launched new proprietary programs like ABCL575 targeting T-cell mediated autoimmune diseases; and completed a $225 million strategic financing round in late 2024 led by existing partners to fuel internal pipeline advancement and AI platform enhancements. The company also advanced clinical milestones, with partner Eli Lilly dosing first patients in Phase 1 for bebtelovimab follow-ons and initiating new GPCR-focused discovery deals. These developments underscore AbCellera's shift toward balancing partner-funded discovery with owned clinical assets amid biotech market dynamics.

Company News

  • AbCellera Biologics Inc. (ABCL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

  • Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year?

  • AbCellera Biologics Eyes Phase 3 for Hot-Flash Drug After Promising Midstage Results

  • AbCellera Biologics Inc. (ABCL) Q3 2026 Earnings Call Transcript

  • What AbCellera Biologics (ABCL) Said on Its Q3 Earnings Call

  • AbCellera Biologics Inc. (ABCL) Reports Q3 Loss, Tops Revenue Estimates

  • AbCellera Reports Q3 2026 Business Results

  • AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

  • AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

  • AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from Analysts

  • ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

  • AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

  • AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

  • BlackRock Inc. Makes New Investment in AbCellera Biologics Inc. $ABCL

  • What'sGoing On With AbCellera Biologics Stock On Tuesday?

  • Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

  • AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

  • What's Going on With AbCellera Biologics Stock On Wednesday?

  • AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

  • Investors Buy Large Volume of AbCellera Biologics Call Options (NASDAQ:ABCL)